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The neuroimaging literature of Major Depressive Disorder (MDD) has grown substantially over the last several
decades, facilitating great advances in the identification of specific brain regions, neurotransmitter systems and
networks associated with depressive illness. Despite this progress, fundamental questions remain about the
pathophysiology and etiology of MDD. More importantly, this body of work has yet to directly influence clinical
practice. It has long been a goal for the fields of clinical psychology and psychiatry to have a means of making
objective diagnoses of mental disorders. Frustratingly little movement has been achieved on this front, however,
and the ‘gold-standard’ of diagnostic validity and reliability remains expert consensus. In light of this challenge, the
focus of the current review is to provide a critical summary of key findings from different neuroimaging approaches
in MDD research, including structural, functional and neurochemical imaging studies. Following this summary, we
discuss some of the current conceptual obstacles to better understanding the pathophysiology of depression, and
conclude with recommendations for future neuroimaging research.
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The neuroimaging literature of Major Depressive Dis-
order (MDD) has exploded in recent years, with the
current pace of research including over 250 new articles
listed each year in PubMed alone. A substantial majority
of these studies have been focused on identifying pu-
tative biological and neural variables that differentiate
individuals with MDD from psychiatrically healthy con-
trols. This program of research has been successful in
demonstrating a large number of abnormalities in MDD
samples, including alterations across measures of brain
structure and function; endocrine, immune and neuro-
transmitter systems; and large-scale network organization.
Despite this progress, however, fundamental questions
remain about the pathophysiology and etiology of MDD
as well as the strengths and pitfalls of neuroimaging meth-
odologies in attempting to answer them.* Correspondence: mtreadway@mclean.harvard.edu; dap@mclean.harvard.
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article, unless otherwise stated.Even more importantly, this body of work has yet to
influence clinical practice in any substantive way. A
longstanding goal of clinical psychology and biological
psychiatry research has been the development of object-
ive tests for diagnosing mental disorders. Frustratingly
little progress has been made on this front, however, and
the ‘gold-standard’ of diagnostic validity and reliability
remains expert consensus, a practice that is essentially
unchanged from Meehl’s day [1]. Despite our capacity to
measure an astonishing array of biological signals in
MDD patients, we have yet to find a single measure - or
a combination of variables - that tracks symptom ex-
pression with the requisite specificity and sensitivity to
be reliably meaningful in the clinic.
It is against this backdrop that we present the current
review. First, we provide a (non-exhaustive) summary of
the major findings that have emerged from different
neuroimaging approaches. This includes a review of struc-
tural, functional, neurochemical, neuroendocrine and neu-
roimmune imaging studies in MDD. Following this
summary, we discuss some of the current conceptual ob-
stacles to better understanding the pathophysiology ofed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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a methodological path forward.
Review
Neuroimaging and the pathophysiology of MDD
Morphometric neuroimaging studies
A large number of studies in MDD patients to date have
identified structural alterations across multiple tissue
classes. These findings have been summarized using me
ta-analytic approaches reporting on structural alter-
ations observed using regions-of-interest (ROI) tracing-
based methods [2,3], voxel-based methods (VBM) [4],
post-mortem tissue analysis [5], and diffusion tensor im-
aging of white-matter integrity [6]. Tracer-based methods
have provided especially strong evidence for reduced
hippocampal volume and enlarged ventricles in MDD
[3]. These results have been recapitulated by voxel-based
methods, which additionally implicate a more distributed
network of structural alterations associated with MDD,
including the anterior cingulate cortex (ACC), medial pre-
frontal cortex (mPFC), orbitofrontal cortex (OFC), dorso-
lateral prefrontal cortex (dlPFC), the striatum, and the
amygdala. A limitation of these findings is that they are
mostly drawn from cross-sectional designs. Therefore, it is
difficult to know whether such structural differences rep-
resent a biological diathesis, a compensatory adaptation,
or a consequence of the illness.
A handful of longitudinal studies have addressed this
significant limitation by investigating structural changes
as a function of depressive state and treatment outcome.
\For some regions, including the hippocampus and medial
prefrontal areas, several studies have suggested that grey-
matter volume may decline monotonically over multiple
depressive episodes [7,8]. In contrast, the amygdala may
become enlarged prior to a first depressive episode [9].
Structural integrity of these regions has also been found to
partially predict symptom remission. Specifically, hippo-
campal volumes have been found to prospectively correl-
ate with treatment outcome at both one- and three-year
follow-ups [10,11], and longitudinal studies have found
that decreased hippocampal volumes were partially restored
following successful treatment or spontaneous remission
[11-13]. Importantly, similar morphometric changes in
these regions have also been associated with high levels
of trait negative affect in non-depressed individuals who
have an elevated polygenic risk profile for developing
MDD. This has been observed using both genome-wide
analysis [14] and examinations of non-depressed indi-
viduals with a family history of MDD [15,16], consistent
with the hypothesis that these structural decreases likely
reflect an endophenotype marker [17].
Taken together, structural imaging studies have found
robust evidence for group-level differences in grey-matter
volume across cortical and sub-cortical areas. Longitudinalstudies provide the strongest evidence linking these
changes to the onset and remission of a depressive state,
suggesting that they are either causally involved in
MDD or that they at least meaningfully fluctuate with
illness progression. Future longitudinal work, especially
with prospective-cohort designs, will help further eluci-
date the role of these morphometric alterations in the
etiopathophysiology of MDD.
Functional neuroimaging studies
Functional imaging studies of MDD have also grown
substantially over the last two decades, with a wide var-
iety of functional domains probed using a large number
of tasks. We will therefore limit our focus to two general
domains that have been most frequently examined in de-
pression studies: (1) emotion processing and regulation,
and (2) reward processing (Figure 1). For a more com-
prehensive discussion of other aspects of the functional
neuroimaging literature in major depression, we refer
readers to several excellent recent reviews and meta-
analyses: [18-20].
Functional neuroimaging of emotion processing Argu-
ably the most common domain assessed by functional
imaging studies of depression is responses to emotional
stimuli. Examples include studies of responses to both
explicit and implicit presentations of affect-laden stimuli
[21-23], recruitment of cognitive control mechanisms re-
quired to gate out affective ‘distractors’ during simple
working memory and attention tasks [24,25], and deli-
berate top-down control of affective responses to positive
and negative stimuli [26-29]. The most replicated result
observed during passive presentation of emotional stimuli
is a heightened responsivity in limbic regions - especially
the amygdala - to negatively valenced stimuli in depressed
individuals. For tasks that require subjects to efficiently
‘gate-out’ affective content in order to better attend to
non-emotional aspects of a task or stimulus, elevated lim-
bic activity is often accompanied by hypo-activation in
prefrontal areas, including aspects of ventromedial PFC,
ventrolateral prefrontal cortex (vlPFC), ACC, and dlPFC.
It is noteworthy that these same regions frequently exhibit
volumetric abnormalities.
While prefrontal hypo-activations are commonly inter-
preted as evidence of a top-down control ‘deficit’, it is
unclear whether they reflect a local deficit in network re-
cruitment or simply a failure to engage in the task as ef-
fectively as controls. Interestingly, when task performance
is matched across depressed and non-depressed individ-
uals, there is evidence for hyper-response in prefrontal
areas [30,31], possibly indicating cortical inefficiency. In
addition, the specificity of alterations in amygdalar and
prefrontal networks to depression is unclear, as similar
patterns are frequently observed in studies of anxiety, and
Figure 1 Regions, transmitters and circuits implicated in the pathology of major depressive disorder (MDD) by human neuroimaging
studies. Past studies have identified alterations in monoamine levels and receptor availability as well as alterations in glutamate and GABA. These
neurotransmitter systems participate in larger circuits involved in the experience and regulation of emotion, responses to stress, and processing of
rewards. Note: placement of structure labels is approximate. Amyg = amygdala; Caud = Caudate; GABA = GABAergic projections; Glu = glutamatergic
projections; Hipp = hippocampus; NAcc = nucleus accumbens; Put = Putamen; SN = substantia nigra; VP = ventral pallidum; VTA = ventral tegmental
area. Republished with permission from Treadway and Zald [49].
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to date [32,33]. Future research is needed to further isolate
the specific alterations in cortico-limbic responses to emo-
tion in MDD, and to determine the extent to which these
effects are specific to a depressed mood or rather repre-
sent a common mechanism associated with other forms of
internalizing psychopathology.
In contrast to experimental paradigms that require
either passive emotional processing or implicit emotion
regulation in the form of attentional control, findings of
studies of directed emotion regulation in MDD are
highly variable. In healthy controls, down-regulation of
negative emotion has been consistently associated with
increased activation in medial and dlPFC areas and re-
duced activity in the amygdala [34]. These observations,
combined with observations of impaired functional
coupling between mPFC and amygdala during passive
viewing of affective stimuli [35], led investigators to
hypothesize that depressed patients would be less suc-
cessful in reducing amygdala reactivity - and associated
negative emotions - when explicitly regulating emo-
tional responses to negative stimuli. Empirical support
for this hypothesis, however, has been mixed. Only one
study has reported that depressed patients experience
more difficulty in decreasing sadness than controls [26],while others have found no differences [27-29]. These
studies have also generally failed to observe impaired
cortico-amygdala interactions during explicit emotion
regulation in MDD. Consequently, these data suggest
that emotion regulation deficits in MDD do not reflect
a true inability to regulate emotion when explicitly di-
rected to do so, at least not in the context of typical
laboratory-based affective stimuli.
Functional neuroimaging of reward processing An-
other primary area of functional neuroimaging research
in MDD involves responses to rewarding stimuli. While
early functional magnetic resonance imaging (fMRI)
(and non-imaging) studies frequently operationalized re-
ward in terms of the passive viewing or consumption of
positively valenced stimuli (for example [36-38]), more
recent work has increasingly emphasized constructs
of reward anticipation [39-42], reinforcement learning
[43,44] and motivation [45-47], which are psychologi-
cally and neurobiologically distinct. This shift has been
motivated largely by the enhanced understanding of
functional segregation of dopaminergic cortico-striatal
systems in reward processing, which have been found to
underlie anticipation, learning, and salience of rewards,
rather than affective responses to them [48]. Indeed,
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translational neuroscience approach, given how well
characterized reward-related pathways are by both pre-
clinical and human neuroeconomic studies (see [49] for a
longer discussion). The most common observation from
this body of work is hypo-recruitment in MDD patients of
striatal regions associated with reward salience, anticipa-
tion and learning, possibly reflecting alterations in the
availability of pre-synaptic pools in dopaminergic afferents
to striatal sub-regions [50-52] (see also discussion of dopa-
mine imaging studies below). In addition, altered cross-
talk between cortical and ventral striatal regions has been
associated with rapid habituation to rewarding stimuli,
which is also consistent with anhedonic presentation [53].
In sum, these studies highlight cortico-striatal path-
ways as critically involved in specific symptom domains
of MDD. Of note, there is arguably greater consistency
in studies of reward processing in MDD than of other
cognitive processes. This may reflect the fact that reward
processing studies have focused on a more homoge-
neous symptom domain and that the neurobiology of
normative reward functioning is better understood.Neurochemical imaging studies in MDD
The hypothesis that specific neurotransmitter systems
represent a core pathology of mood disorders is among
the oldest in biological psychiatry (see, for example,
Schildkraut [54]). For most of modern psychiatric history,
this line of work has emphasized alterations in mono-
amines, given early observations that administration of
various monoamine-reducing drugs or pharmacological
manipulations could induce depressive symptoms. It was
only decades later, however, when the in vivo visualization
of these signaling pathways could be achieved.
Currently, the two most widely used approaches to
neurochemical imaging in psychiatric populations are
Positron Emission Tomography (PET) and Magnetic
Resonance Spectroscopy (MRS). A less commonly used
technique is Single Photon Emission Computed Tom-
ography (SPECT). Both PET and SPECT rely on the
measurement of radioactive decay from an injected iso-
tope as the basis of targeting the spatial distribution of a
particular receptor or protein. In contrast, MRS takes
advantage of the different magnetic resonance signa-
tures associated with distinct molecular compounds,
and can be useful for quantifying the availability of rela-
tively abundant neurotransmitters such as glutamate
(Glu) and γ-aminobutyric acid (GABA). Both of these
methods have contributed to the study of pathophysi-
ology in MDD, and are notable for both their positive
and null findings. In this section, we review some of the
primary neurotransmitter systems that have been inves-
tigated in MDD using these techniques.Neurochemical imaging of serotonin systems in MDD
Interest in serotonin (5-HT) has been central to depres-
sion research over the last three decades, owing primarily
to reported success of antidepressant pharmacotherapies
that selectively target the serotonergic system in both
humans and animal models. Evidence from preclinical
studies further supports a role for serotonin in MDD
symptoms, particularly those related to the processing of
stress. Under normal conditions of wakefulness, serotonin
neurons are tonically active [55] and the distribution of se-
rotonergic tone is relatively even across most brain regions
[56] - a pattern that has been found to support normal
network functioning for a variety of cognitive and goal-
directed behaviors. In contrast, exposure to stress can pro-
duce a surge in 5-HT signaling, which has been found
to disrupt the emotion-regulatory functions of cortico-
amygdalar networks [57]. Further, evidence suggests that
medial prefrontal projections to serotonin-releasing neu-
rons in the dorsal raphe play a crucial role in determining
adaptive versus non-adaptive responses to stress [58,59].
Consequently, impaired serotonin signaling may be a sub-
strate involved in stress vulnerability and a key risk factor
in the development of MDD [60-62].
For these reasons, serotonin is among the most widely
imaged neurochemical systems in MDD, with over 35
studies exploring group differences in the expression of
serotonin receptor sub-types as well as the serotonin
transporter (for recent reviews, see [63,64]). To date,
however, results have been mixed, with investigators fre-
quently reporting higher or lower serotonin receptor or
transporter expression in MDD participants than in con-
trols [63]. For example, of the 15 studies investigating
expression of 5-HT1A receptor in depressed patients
relative to healthy controls, nine reported decreased ex-
pression in MDD, four reported increased expression,
and two observed no change. Similar discrepancies have
been observed for other proteins involved in 5-HT sig-
naling pathways, including the 5-HT2A receptor, 5-HT1B
receptor, and the serotonin transporter (SERT).
It is important to note that most of these studies are
relatively small in size (between 9 and 22 MDD patients)
and are, therefore, underpowered to explore within-
sample relations between serotonin function and specific
symptom dimensions. This is a potentially critical limita-
tion, as the substantial heterogeneity of MDD is likely to
be associated with divergent effects on neurotransmitter
systems. In addition, most of these studies have not in-
vestigated the function of serotonin signaling systems,
compared to baseline expression. Moreover, no longitu-
dinal studies have been performed. Therefore, as with
cross-sectional studies of structure or function, it is diffi-
cult to know whether 5HT abnormalities should be
interpreted as a primary deficit, a downstream conse-
quence, a risk factor, or a compensatory mechanism.
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5-HT system is involved in the etiopathophysiology, its
effect size is modest, and likely dependent on interac-
tions with numerous other systems.
Neurochemical imaging of catecholamine systems in
MDD Other monoamines that have long been associ-
ated with MDD are the catecholamines dopamine (DA)
and norepinephrine (NE) [65,66]. DA is well established
as being necessary for motivation, reward-based learn-
ing, and goal-directed behavior [48,67,68] and, therefore,
is believed to be a substrate of reward-related symptoms
such as anhedonia, fatigue, and anergia in psychiatric
disorders [69,70]. Unlike 5-HT, which is relatively uni-
form in its distribution across the brain, DA expression
is densest in the striatum, a key structure involved in
valuation, decision-making and action.
Neuroimaging evidence for altered DA systems in MDD
comes primarily from PET, SPECT and pharmacological
challenge studies. This research has found that MDD
is associated with changes in DA synthesis capacity as
indexed by L-3,4-dihydroxyphenylalanine (L-DOPA) up-
take [71], as well as changes in the regional distribution
and availability of DA receptors, and the DA transporter
(DAT). As with the 5-HT studies summarized above, how-
ever, imaging studies of DA systems have produced con-
flicting results. In PET and SPECT studies of DAT, MDD
has been associated with both lower [72] and higher
[73-75] binding potential in the striatum. Interestingly, all
studies reporting DAT increases have used SPECT, which
has much lower sensitivity than PET [76] and often
employed tracers that have equal affinity for the SERT
and DAT (for example, β-CIT) and thus do not allow con-
clusive interpretations. Moreover, post-mortem studies
support the observation of reduced DAT expression [77].
Studies of DA receptor availability in MDD have also
yielded mixed results. In some cases, increased striatal
D2/D3 receptor binding has been shown to occur in het-
erogeneous depressed samples [78,79]. This increase in
D2/D3 receptor availability appears to contradict animal
data in which antidepressant responses are associated
with increased D2-like binding in the striatum [80].
Other studies using medication-naïve or medication-free
patients have failed to find group differences in striatal
receptor binding [81,82], while one additional small
study reported variable changes in D2-like binding fol-
lowing treatment with selective serotonin reuptake in-
hibitors (SSRIs) with patients who showed increased
binding exhibiting more clinical improvement than
those who did not [83]. With respect to the D1 receptor,
fewer studies have examined this system given the lack
of available ligands that reliably distinguish between the
D1 and serotonin 5-HT2A receptor, especially in extra-
striatal areas where the receptor density of D1 and 5HT2Ais roughly equivalent. One study reported reduced D1
availability in left middle caudate [84], but this finding
has not yet been replicated. Taken together, these studies
suggest a possible role of D2-like receptors in downstream
effects of antidepressant treatment, although the precise
nature of the effect and how alterations in D2-like recep-
tor availability may be related to DA function are unclear.
As with other conflicting reports in neuroimaging
studies of MDD, part of the discrepancy across studies
likely reflects the heterogeneity of the disorder. Support-
ing this assertion is the observation of slightly more con-
sistent effects when MDD samples are selected on the
basis of a particular symptom profile. For example, one
study that restricted its MDD patient sample to individ-
uals with anhedonic symptoms reported decreased DAT
binding [85]. In addition, L-DOPA alterations in the stri-
atum are present in depressed individuals with flat affect
or psychomotor slowing, but not in depressed individuals
without these symptoms [86,87]. Decreases in DA synthe-
sis have also been observed in patients who develop de-
pressive symptoms after undergoing IFN-α therapy [50].
This therapy stimulates inflammation signaling cascades,
which have been found to disrupt DA synthesis, and may
provide a link between elevated inflammation in MDD
and specific symptoms related to perturbances of DA
signaling, such as motivation and anhedonia [50,88].
Overall, these studies provide mixed evidence for gen-
eral DA alterations in MDD, with additional evidence
highlighting the importance of examining links between
DA systems and specific symptoms in MDD, rather than
in the disorder as a whole.
In contrast to DA, molecular imaging methods of NE
signaling pathways have been much slower to develop.
Currently, only studies of the NE transporter (NET) have
been performed in MDD [89], with no studies examining
NE receptors in MDD due to a lack of available ligands.
Pharmacological functional imaging studies have also been
used to indirectly explore effects of NE-increasing agents,
though many of these studies have used drugs such as
duloxetine, which simultaneously target both 5-HT and
NE transporters. Duloxetine reduced connectivity within
resting-state and task-positive networks, [90], and boosted
ventral striatal responses during a reward task [91], while
the NET-selective agent reboxetine increased thalamic
dorsolateral prefrontal responsivity to emotional pic-
tures [92,93]. While these studies provide promising
leads, insufficient functional or molecular imaging work
of NE function in the context of MDD is available, des-
pite significant evidence for its role in the disorder [94].
Neurochemical imaging of glutamatergic and GABAergic
systems in MDD In recent years there has been sub-
stantial interest in the contribution of non-monoamine
neurotransmitters to the pathophysiology of MDD,
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mitters of glutamate (Glu) and GABA, respectively. At an
intuitive level, the hypothesis that these systems would be
implicated in depression holds significant appeal; the in-
nervation of Glu- and GABA-releasing neurons vastly out-
numbers all other neurotransmitter systems in the brain,
making these two neurochemicals responsible for the bulk
of information processing related to learning, cognition,
memory, and decision-making [95]. When considering the
scope of this diverse functional anatomy, it is difficult to
imagine that Glu and GABA would not be directly, or at
least indirectly, involved.
Evidence for alterations of Glu transmission in MDD
have long been reported, but findings have been mixed,
with increased Glu levels observed in plasma samples
and post-mortem tissue as compared to decreased levels
found in neuroimaging studies [96-98]. These discrepan-
cies may be due in part to the multiple roles that Glu
plays in the brain (for a more extended discussion, see
[99]). A recent meta-analysis or MRS imaging studies
found that MDD was associated with a substantial de-
crease in Glu levels within the mPFC/ACC [100], though
it should be noted that not all studies were able to dis-
tinguish between Glu and glutamine, a common metab-
olite of astrocyte reuptake processes. Studies published
after this meta-analysis provided additional evidence of
reduced Glu concentration in the mPFC of MDD sub-
jects [101-103], and similar alterations have also been
detected in children with depressive symptoms [104] as
well as remitted MDD subjects [102], raising the possi-
bility that they constitute a trait-like vulnerability factor
for MDD. Highlighting the clinical significance of these
findings, among MDD subjects, increased pre-treatment
Glu levels predicted better electroconvulsive therapy
(ECT) response [103].
PET imaging studies of metabotropic Glu receptors
have also revealed changes in Glu signaling pathways in
MDD [105] and in relation to MDD symptoms [106]. The
rapid antidepressant effects of ketamine, an N-methyl-D-
aspartate (NMDA) partial agonist [107,108] further impli-
cate the Glu pathway. Finally, aberrations in Glu signaling
and Glu neurotoxicity have been associated with mPFC
volumetric reductions discussed above [95]. In sum, while
investigation of Glu dysfunction in MDD is relatively new,
given the near ubiquitous distribution of Glu signaling
throughout the brain, it is likely that many of the alter-
ations in neural circuit function observed using fMRI
studies partially reflect Glu-related pathology.
In contrast to Glu, studies of GABA are less frequent in
MDD. GABA alterations have been documented in MDD
[17,109], including reports of reduced GABA levels in
plasma and cerebrospinal fluid [110-112], as well as spe-
cific GABA reductions in the mPFC as assessed with MRS
[113,114]. Moreover, GABA function in this region hasbeen suggested to play a critical role in mediating negative
feedback of hypothalamic-pituitary-adrenal (HPA)-axis
activity [115,116]. Thus, decreased GABAergic tone
may foment excess glucocorticoid exposure in mPFC,
as reviewed above. The combination of increased glu-
cocorticoid exposure and elevated GABA has been
hypothesized to be a combination that may lead to in-
creased excitotoxicity in these regions, thereby partially
explaining the structural alterations in these areas sum-
marized in the preceding section. To date, however, the
number of studies focused on GABA is relatively small,
making it difficult to draw firm conclusions.
Imaging neuroendocrine and neuroimmune systems
in MDD Lastly, there has been growing interest in using
neuroimaging to study the functional and structural con-
sequence of other neurochemicals, such as hormones,
factors and other endogenous signaling molecules. While
technical limitations generally prevent the imaging of
such molecules directly, their effects on structure and
metabolism can nevertheless be observed using MRI. In
the case of MDD, this work has focused most heavily on
pro-inflammatory factors, including families of cytokines
such as interleukins and interferons, hormones such as
glucocorticoids (cortisol), thyroid stimulating hormone
(TSH), and ghrelin [117,118].
Dysregulation of stress hormones has been widely re-
ported in MDD (albeit with significant variance), and is
believed to partially mediate some of the observed struc-
tural alterations associated with the disorder, especially
within the hippocampus and mPFC [119,120]. These re-
gions are well known for playing a critical role in the
regulation of stress hormones via direct and indirect
projections to the hypothalamus, and have been shown
to be structurally vulnerable to glucocorticoid-mediated
excitotoxicity. Animal studies using either chronic stress
protocols or local corticosteroid injections have repeat-
edly demonstrated tissue damage following excessive
glucocorticoid exposure, including loss of dendritic
spines and de-arborization [121-124]. In human studies,
comparable relationships have been observed between
daily cortisol levels and grey-matter volume in depressed
patients [125]. Given that elevated stress is a major pre-
cipitant of first-time depressive episodes [60], the associ-
ation between stress and regional microdamage is highly
relevant.
In addition to stress hormones, depressive states have
been strongly associated with an elevated inflammatory
load [126,127], and there has been growing interest in sig-
naling pathways related to the metabolic syndrome and
excess adipose tissue as potential mediators of chronic
low-grade inflammation [128,129]. Neuroimaging has
therefore been employed as an aid to understanding
the possible consequences of altered inflammatory and
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models suggest that elevations of peripheral cytokines
and subsequent CNS microglia activation can disrupt
the synthesis of both 5-HT and DA [132,133], and in-
duce symptoms of fatigue and motivational anhedonia
[134,135]. While direct evidence of increased microglia
activity in MDD has not been detected using available
PET ligands [136], functional neuroimaging studies
have sought to better understand the downstream con-
sequences of increased cytokine activity by examining
correlations between peripheral cytokine levels and
resting or task-induced fluctuations in Blood-Oxygen-
Level Dependent (BOLD) signals. Of note, healthy con-
trols receiving an endotoxin challenge exhibited blunted
neural responses to reward anticipation in the ventral stri-
atum during a Monetary Incentive Delay (MID) task
[137], similar to what is observed in MDD [42]. Further
evidence comes from imaging studies of patients receiving
IFN-α therapy. Following IFN-α treatment - which ro-
bustly increases inflammation - subjects exhibited de-
creased DA turnover within the striatum, as measured
using a pre/post PET imaging of DA uptake with [18 F]
Dopa (F-DOPA) [50]. By beginning to localize the func-
tional architecture of brain regions that are affected by
stress hormones and inflammation and by linking such
abnormalities to specific cardinal symptoms of MDD (for
example, anhedonia), these studies are playing a critical
role in advancing a more precise understanding of depres-
sion symptomatology.
Summary of neuroimaging studies In review of the
findings above, several themes emerge. The most prom-
ising result is that regardless of imaging modality, neuro-
imaging studies repeatedly isolate a similar network of
regions in which MDD patients differ from controls. In-
deed, the greatest success of neuroimaging studies in
MDD has been to identify core nodes involved in the ex-
pression of depressive symptoms. Neural responses in
cortico-striato-limbic circuits have been shown to discrim-
inate between responders to different treatment modalities
[20,138] and have been the empirical foundation for new
treatment techniques, such as deep brain stimulation
(DBS) [139,140] and transcranial magnetic stimulation
(TMS) [141].
But this is perhaps where the good news ends; for
while the same regions are often implicated, the direc-
tion of the effects is often contradictory (for example,
greater or lesser BOLD signal, depending on the task).
Moreover, some of this consistency is undoubtedly due
to confirmatory bias in ROI selection; that is, reports of
group differences in a given region increase the prob-
ability that future studies will focus on the region, either
with targeted measurement (for example, volumetric tra-
cing) or with more liberal statistical thresholds in voxel-based studies (for example, small-volume correction).
Even when group differences emerge, they are often
present only at the level of group average, with compar-
able ranges for both groups (for example, [142]). As a
result, the field has been unable to identify any neural
signature that may serve as useful biomarker in the
diagnosis of MDD, and guide treatment selection.
The lack of stable pathophysiological markers of MDD
after so many neuroimaging studies raises the possibility
that the biological origins of depressive symptoms are
simply too dynamic to produce consistent patterns using
case–control designs. For example, many receptor sub-
types, including those of monoamine, Glu and GABA
pathways show rapid, activity-dependent changes in ex-
pression and ligand affinity [143]. This plasticity may be
affected by the time of day, the amount of sleep some-
one received two nights before, and how much they have
been taxing their working memory in recent weeks just
as much as it is affected by MDD ([105,143]). Against all
these additional sources of variance, it is perhaps unsur-
prising that cross-sectional designs have been unable to
identify reliable biomarkers.
As a result, an increasing number of researchers have
called for a better understanding of specific circuits
that may mediate transdiagnostic symptom expression
[144,145]. While much of this discussion has rightly em-
phasized the importance of animal models [146,147], the
final section presents several conceptual and methodo-
logical approaches to clinical imaging studies that we
feel may aid in the identification of circuits rather than
regions.
Future directions and circuit-based analysis
A clear limitation of current neuroimaging studies in
MDD has been the tendency to assess particular mea-
sures of brain function independently, despite clear evi-
dence that these measures are highly inter-related. In
contrast to measures of specific brain regions, chemicals,
or tissue classes, circuit-based analysis provides a con-
ceptual framework that is organized around a specific
behavioral process. Circuits are defined by the combined
structural and functional properties that enable a spe-
cific set of computations to be performed on a discrete
set of inputs. As such, circuit-analysis integrates across
many different levels and measures of brain function,
but eschew the complexity of simultaneous whole-brain
analysis. By focusing on discrete computations with a
circumscribed array of possible inputs and outputs, cir-
cuit analysis meets the basic scientific requirement of
simplification, but does so without neglecting biological
complexity.
One of the most powerful and readily available methods
for circuit-analysis in patient populations is functional
connectivity. Whereas much of the first two decades of
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tion to a particular brain region while individuals were
either at rest or performing a particular task, growing ap-
preciation for the role of functional networks has emerged
in recent years. This shift reflects a broader recognition in
the field of neuroimaging that the brain is comprised of
discrete networks, which show local properties (for ex-
ample, ‘small-worldness’) and can rapidly re-configure
themselves to adapt to current environmental demands
[148,149]. Consequently, focusing on task-driven changes
within a single brain area provides only limited insight
into the specific computations being performed. Indeed,
significant progress has been made in the characterization
of several stable networks that support domain-general
functions, including attentional control, novelty and threat
detection, default-mode and social cognition, and rein-
forcement learning and decision-making, all of which have
been implicated in MDD [150] (Figure 2).
Complementing functional connectivity as a path to-
wards understanding MDD from a systems-level ap-
proach is the growing use of multi-modal imaging. The
most common example is the combined use of struc-
tural and function neuroimaging data. Such data are
often collected together, as standard preprocessing pipe-
lines for functional neuroimaging data typically require
high-resolution structural scans [151]. More recently,Figure 2 Schematic depiction of commonly identified functional netw
Republished with permission from Buckholtz and Meyer-Lindenberg [150].the scope of multi-modal imaging studies has been ex-
panded to include neurotransmitters such as monoamines,
Glu and GABA. In an important study by Northoff and
colleagues, researchers identified shifts in neurotransmit-
ter availability of Glu and GABA as major drivers of al-
tered functional responses to emotional stimuli in MDD
[152]. Similarly, decreases in pre-synaptic striatal DA as
measured using F-DOPA were associated with blunted
ventral striatal BOLD signal during reward anticipation in
depressed subjects, demonstrating a clear link between
DA bioavailability and striatal responses to reward [50].
Another essential benefit of circuit-based analysis is the
bridge it creates to behavioral and molecular neuroscience.
Animal models play a pivotal role in testing causal hypoth-
eses about brain function [146]. Such models are not only
useful in aiding the interpretation of correlative neuroim-
aging data, they can also help refine the mapping of psy-
chiatric symptom definitions to discrete and dissociable
circuits. For example, the symptom of anhedonia - which
was once perceived as a unitary construct tapping into the
experience of pleasure - has gradually come to be recog-
nized as involving multiple sub-components, including
motivation and hedonic response, each of which involves
distinct neural substrates [69,70,153]. However, because
these sub-components in humans are often heavily corre-
lated with each other at the level of symptom expression,orks and their associated cognitive and symptom domains.
Treadway and Pizzagalli Biology of Mood & Anxiety Disorders 2014, 4:5 Page 9 of 13
http://www.biolmoodanxietydisord.com/content/4/1/5animal models were required to demonstrate that motiv-
ational and hedonic aspects of reinforcement were indeed
neurobiologically dissociable [48,67].
Pharmacological manipulations and other interven-
tional techniques also provide tremendous advantages
over imaging measures alone; these studies can identify
plasticity dynamics that can help unpack some of the
cross-sectional observations. For example, behavioral
pharmacology studies of DA in MDD suggest that pa-
tients experience a much stronger euphoria response to
amphetamine than controls [154,155], possibly indicat-
ing an up-regulation of post-synaptic DA receptors sites
and/or DAT. The cross-sectional imaging studies dis-
cussed above, however, suggest down-regulation of both
D1 and D2 as well as DAT proteins. Since the expression
of these proteins is dynamic, imaging studies done in
conjunction with pharmacological challenges (within-
subject) hold the promise for stronger mechanistic infer-
ences regarding how neurotransmitter systems are able
to adapt to changing conditions in MDD. Such pharma-
cological challenges can therefore greatly aid in the un-
derstanding of plasticity within circuits, and help shift
away from a focus on the identification of a stable, per-
sistent pathological marker, which appears unlikely to
exist.
Finally, circuit-based analysis may help facilitate a shift
in the conceptualization and measurement of psychiatric
symptom inventories that are often used to define
groups and regress against imaging data. Psychiatric
measurement largely relies on subjective self-reporting
of distress as they sine qua non of symptom diagnosis.
When it comes to reporting how one feels, however, stud-
ies in healthy populations have increasingly observed dis-
sociation between the ‘believing self ’ and the ‘experiencing
self ’ [156-158]. Accordingly, while the former describes
how an individual summarizes their experience over a
period of time, the latter refers to experiential reports
made ‘in the moment’. Whereas these constructs would
theoretically be expected to correlate highly, growing evi-
dence suggests that they are only moderately correlated at
best [157,159]. This is in part due to the presence of well-
known retrospective biases that reflect a heightened
sensitivity to recency or maximum intensity of emo-
tional experiences (so-called ‘peak and end’ effects)
[160]. In disorders like schizophrenia, such retrospect-
ive biases can result in almost completely uncorrelated
findings of emotional response across retrospective and
in-the-moment reports [161].
This renders significantly liable the common practice
of regressing symptom severity measures (for example,
the BDI-II) against imaging data [162], as both the inde-
pendent and dependent measures likely reflect a com-
plex mix of ‘believing self ’ and ‘experiencing self ’. For
example, if someone has reported severe depression overthe past week, but happens to have a brief lifting during
the two- to three-hour window in which the lab experi-
ment occurs, it may be more important to consider the
‘in the moment’ affect rather than feelings aggregated
over the past weeks when trying to interpret associated
imaging data; this stands in contrast with the traditional
assumption that individuals with shared symptom seve-
rity over a one-week period will have more variance in
common than individuals with shared experience of a
particular experimental task. One approach to address-
ing this challenge is the development of measures that
seek to tease apart ‘believing self ’ and ‘experiencing self ’,
with the aim of identifying separate biological correlates.
It is likely that both are implicated in the maintenance
of depressive symptoms [163], but current symptom as-
sessment inventories are poorly suited to distinguish be-
tween these distinct modes of types of subjective report.
In sum, clinical imaging studies can contribute to
circuit-based analysis through a focus on network-based
analytical techniques, such as functional connectivity,
multi-modal imaging methods, the use of within-subject
pharmacological challenge designs, and greater sensitivity
to potential discrepancies between ‘believing self ’ and
‘experiencing self ’ that may mask important distinctions
in the relationships between subjective report and neu-
roimaging data.Conclusion
The neuroimaging literature of depression has grown
tremendously over the last several decades. The primary
fruit of these efforts has been the identification of brain
regions and structures that are most critical to the expres-
sion of depressive symptomatology, while also increasing
our knowledge of how these regions interact with particu-
lar neurotransmitter systems, neurochemicals, hormones,
and other signaling proteins. Despite a wealth of positive
findings, translations to treatment remain elusive. Moving
forward, the integration of these various methods through
the use of circuit-based analysis will be critical for the de-
velopment of a biologically-based nosology and personal-
ized medicine in psychiatry.Abbreviations
5-HT: Serotonin; ACC: anterior cingulate cortex; BOLD: blood-oxygen
level-dependent; CNS: central nervous system; DA: dopamine;
DAT: dopamine transporter; DBS: deep-brain stimulation; dlPFC: dorsolateral
prefrontal cortex; Glu: glutamate; GABA: gamma-aminobutyric acid; HPA
axis: hypothalamic-pituitary-adrenal axis; IFN: interferon; MDD: major
depressive disorder; MID: monetary incentive delay; mPFC: medial prefrontal
cortex; MRI: magnetic resonance imaging; MRS: magnetic resonance
spectroscopy; NE: norepinephrine; NET: norepinephrine transporter;
OFC: orbitofrontal cortex; PET: positron emission tomography; PFC: prefrontal
cortex; ROI: region of interest; SPECT: single photon emission computed
tomography; SERT: serotonin transporter; TMS: transcranial magnetic
stimulation; TSH: thyroid stimulating hormone; VBM: voxel-based
morphometry; vlPFC: ventrolateral prefrontal cortex.
Treadway and Pizzagalli Biology of Mood & Anxiety Disorders 2014, 4:5 Page 10 of 13
http://www.biolmoodanxietydisord.com/content/4/1/5Competing interests
The authors declare no competing interests. Over the past three years,
Dr. Pizzagalli received consulting/honoraria from AstraZeneca, Ono Pharma
USA, Pfizer, Servier, and Shire for activities unrelated to the current review.
Authors’ contributions
MTT and DAP developed the outline, MTT reviewed the relevant literature,
and MTT and DAP wrote the manuscript. Both authors read and approved
the final manuscript.
Acknowledgements
This work was funded by R01MH068376, R01MH06376S1, and R01MH095809
to DAP, and a McLean Corneel Fellowship to MTT. The authors also wish to
thank two anonymous reviewers for their helpful comments.
Received: 19 November 2013 Accepted: 17 February 2014
Published: 7 March 2014
References
1. Kapur S, Phillips AG, Insel TR: Why has it taken so long for biological
psychiatry to develop clinical tests and what to do about it? Mol
Psychiatry 2012, 17:1174–1179.
2. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS:
Brain volume abnormalities in major depressive disorder: a meta-analysis of
magnetic resonance imaging studies. Hum Brain Mapp 2009.
3. Kempton MJ, Salvador Z, Munafo MR, Geddes JR, Simmons A, Frangou S,
Williams SC: Structural neuroimaging studies in major depressive
disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen
Psychiatry 2011, 68:675–690.
4. Bora E, Fornito A, Pantelis C, Yucel M: Gray matter abnormalities in Major
Depressive Disorder: a meta-analysis of voxel based morphometry
studies. J Affect Disord 2011, 138:9–18.
5. Cotter D, Mackay D, Landau S, Kerwin R, Everall I: Reduced glial cell density
and neuronal size in the anterior cingulate cortex in major depressive
disorder. Arch Gen Psychiatry 2001, 58:545–553.
6. Liao Y, Huang X, Wu Q, Yang C, Kuang W, Du M, Lui S, Yue Q, Chan RC,
Kemp GJ, Gong Q: Is depression a disconnection syndrome? Meta-analysis
of diffusion tensor imaging studies in patients with MDD. J Psychiatry
Neurosci 2013, 38:49–56.
7. Yucel K, McKinnon MC, Chahal R, Taylor VH, Macdonald K, Joffe R,
MacQueen GM: Anterior cingulate volumes in never-treated patients with
major depressive disorder. Neuropsychopharmacology 2008, 33:3157–3163.
8. McKinnon MC, Yucel K, Nazarov A, MacQueen GM: A meta-analysis
examining clinical predictors of hippocampal volume in patients with
major depressive disorder. J Psychiatry Neurosci 2009, 34:41–54.
9. van Eijndhoven P, van Wingen G, van Oijen K, Rijpkema M, Goraj B, Jan
Verkes R, Oude Voshaar R, Fernandez G, Buitelaar J, Tendolkar I: Amygdala
volume marks the acute state in the early course of depression. Biol
Psychiatry 2009, 65:812–818.
10. Frodl T, Meisenzahl EM, Zetzsche T, Hohne T, Banac S, Schorr C, Jager M,
Leinsinger G, Bottlender R, Reiser M, Moller HJ: Hippocampal and
amygdala changes in patients with major depressive disorder and
healthy controls during a 1-year follow-up. J Clin Psychiatry 2004,
65:492–499.
11. Frodl T, Jager M, Smajstrlova I, Born C, Bottlender R, Palladino T, Reiser M,
Moller HJ, Meisenzahl EM: Effect of hippocampal and amygdala volumes
on clinical outcomes in major depression: a 3-year prospective magnetic
resonance imaging study. J Psychiatry Neurosci 2008, 33:423–430.
12. Arnone D, McKie S, Elliott R, Juhasz G, Thomas EJ, Downey D, Williams S,
Deakin JF, Anderson IM: State-dependent changes in hippocampal grey
matter in depression. Mol Psychiatry 2012.
13. Schermuly I, Wolf D, Lieb K, Stoeter P, Fellgiebel A: State dependent
posterior hippocampal volume increases in patients with major
depressive disorder. J Affect Disord 2011, 135:405–409.
14. Holmes AJ, Lee PH, Hollinshead MO, Bakst L, Roffman JL, Smoller JW,
Buckner RL: Individual differences in amygdala-medial prefrontal anatomy
link negative affect, impaired social functioning, and polygenic depression
risk. J Neurosci 2012, 32:18087–18100.
15. Saleh K, Carballedo A, Lisiecka D, Fagan AJ, Connolly G, Boyle G, Frodl T:
Impact of family history and depression on amygdala volume. Psychiatry
Res 2012, 203:24–30.16. Amico F, Meisenzahl E, Koutsouleris N, Reiser M, Moller HJ, Frodl T:
Structural MRI correlates for vulnerability and resilience to major
depressive disorder. J Psychiatry Neurosci 2011, 36:15–22.
17. Hasler G, Northoff G: Discovering imaging endophenotypes for major
depression. Mol Psychiatry 2011, 16:604–619.
18. Diener C, Kuehner C, Brusniak W, Ubl B, Wessa M, Flor H: A meta-analysis of
neurofunctional imaging studies of emotion and cognition in major
depression. Neuroimage 2012, 61:677–685.
19. Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH:
Functional neuroimaging of major depressive disorder: a meta-analysis
and new integration of base line activation and neural response data.
Am J Psychiatry 2012, 169:693–703.
20. Pizzagalli DA: Frontocingulate dysfunction in depression: toward
biomarkers of treatment response. Neuropsychopharmacology 2011,
36:183–206.
21. Victor TA, Furey ML, Fromm SJ, Ohman A, Drevets WC: Relationship
between amygdala responses to masked faces and mood state and
treatment in major depressive disorder. Arch Gen Psychiatry 2010,
67:1128–1138.
22. Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J, Andrew CM,
Pich EM, Williams PM, Reed LJ, Mitterschiffthaler MT, Suckling J, Bullmore ET:
Attenuation of the neural response to sad faces in major depression by
antidepressant treatment: a prospective, event-related functional
magnetic resonance imaging study. Arch Gen Psychiatry 2004, 61:877–889.
23. Siegle GJ, Steinhauer SR, Thase ME, Stenger VA, Carter CS: Can’t shake that
feeling: event-related fMRI assessment of sustained amygdala activity in
response to emotional information in depressed individuals. Biol
Psychiatry 2002, 51:693–707.
24. Mitterschiffthaler MT, Williams SC, Walsh ND, Cleare AJ, Donaldson C, Scott
J, Fu CH: Neural basis of the emotional Stroop interference effect in
major depression. Psychol Med 2008, 38:247–256.
25. Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME: Increased
amygdala and decreased dorsolateral prefrontal BOLD responses in
unipolar depression: related and independent features. Biol Psychiatry
2007, 61:198–209.
26. Beauregard M, Paquette V, Levesque J: Dysfunction in the neural circuitry
of emotional self-regulation in major depressive disorder. Neuroreport
2006, 17:843–846.
27. Dillon DG, Pizzagalli DA: Evidence of successful modulation of brain
activation and subjective experience during reappraisal of negative
emotion in unmedicated depression. Psychiatry Res 2013, 212:99–107.
28. Erk S, Mikschl A, Stier S, Ciaramidaro A, Gapp V, Weber B, Walter H: Acute
and sustained effects of cognitive emotion regulation in major
depression. J Neurosci 2010, 30:15726–15734.
29. Johnstone T, van Reekum CM, Urry HL, Kalin NH, Davidson RJ: Failure to
regulate: counterproductive recruitment of top-down prefrontal-subcortical
circuitry in major depression. J Neurosci 2007, 27:8877–8884.
30. Matsuo K, Glahn DC, Peluso MA, Hatch JP, Monkul ES, Najt P, Sanches M,
Zamarripa F, Li J, Lancaster JL, Fox PT, Gao JH, Soares JC: Prefrontal
hyperactivation during working memory task in untreated individuals
with major depressive disorder. Mol Psychiatry 2007, 12:158–166.
31. Wagner G, Sinsel E, Sobanski T, Kohler S, Marinou V, Mentzel HJ, Sauer H,
Schlosser RG: Cortical inefficiency in patients with unipolar depression:
an event-related FMRI study with the Stroop task. Biol Psychiatry 2006,
59:958–965.
32. Etkin A, Schatzberg AF: Common abnormalities and disorder-specific
compensation during implicit regulation of emotional processing in
generalized anxiety and major depressive disorders. Am J Psychiatry 2011,
168:968–978.
33. Beesdo K, Lau JY, Guyer AE, McClure-Tone EB, Monk CS, Nelson EE, Fromm
SJ, Goldwin MA, Wittchen HU, Leibenluft E, Ernst M, Pine DS: Common and
distinct amygdala-function perturbations in depressed versus anxious
adolescents. Arch Gen Psychiatry 2009, 66:275–285.
34. Ochsner KN, Ray RD, Cooper JC, Robertson ER, Chopra S, Gabrieli JD, Gross
JJ: For better or for worse: neural systems supporting the cognitive
down- and up-regulation of negative emotion. Neuroimage 2004,
23:483–499.
35. Matthews SC, Strigo IA, Simmons AN, Yang TT, Paulus MP: Decreased
functional coupling of the amygdala and supragenual cingulate is
related to increased depression in unmedicated individuals with current
major depressive disorder. J Affect Disord 2008, 111:13–20.
Treadway and Pizzagalli Biology of Mood & Anxiety Disorders 2014, 4:5 Page 11 of 13
http://www.biolmoodanxietydisord.com/content/4/1/536. Mitterschiffthaler MT, Kumari V, Malhi GS, Brown RG, Giampietro VP,
Brammer MJ, Suckling J, Poon L, Simmons A, Andrew C, Sharma T: Neural
response to pleasant stimuli in anhedonia: an fMRI study. Neuroreport
2003, 14:177–182.
37. Surguladze S, Brammer MJ, Keedwell P, Giampietro V, Young AW, Travis MJ,
Williams SC, Phillips ML: A differential pattern of neural response toward
sad versus happy facial expressions in major depressive disorder. Biol
Psychiatry 2005, 57:201–209.
38. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML: A double
dissociation of ventromedial prefrontal cortical responses to sad and
happy stimuli in depressed and healthy individuals. Biol Psychiatry 2005,
58:495–503.
39. Gotlib IH, Hamilton JP, Cooney RE, Singh MK, Henry ML, Joormann J: Neural
processing of reward and loss in girls at risk for major depression. Arch
Gen Psychiatry 2010, 67:380–387.
40. Dichter GS, Felder JN, Petty C, Bizzell J, Ernst M, Smoski MJ: The effects of
psychotherapy on neural responses to rewards in major depression. Biol
Psychiatry 2009, 66:886–897.
41. Forbes EE, Hariri AR, Martin SL, Silk JS, Moyles DL, Fisher PM, Brown SM,
Ryan ND, Birmaher B, Axelson DA, Dahl RE: Altered striatal activation
predicting real-world positive affect in adolescent major depressive
disorder. Am J Psychiatry 2009, 166:64–73.
42. Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, Dougherty
DD, Iosifescu DV, Rauch SL, Fava M: Reduced caudate and nucleus
accumbens response to rewards in unmedicated individuals with major
depressive disorder. Am J Psychiatry 2009, 166:702–710.
43. Kumar P, Waiter G, Ahearn T, Milders M, Reid I, Steele JD: Abnormal
temporal difference reward-learning signals in major depression. Brain
2008, 131:2084–2093.
44. Pizzagalli DA, Iosifescu D, Hallett LA, Ratner KG, Fava M: Reduced hedonic
capacity in major depressive disorder: evidence from a probabilistic
reward task. J Psychiatr Res 2008, 43:76–87.
45. Clery-Melin ML, Schmidt L, Lafargue G, Baup N, Fossati P, Pessiglione M:
Why don’t you try harder? An investigation of effort production in major
depression. PLoS One 2011, 6:e23178.
46. Sherdell L, Waugh CE, Gotlib IH: Anticipatory pleasure predicts motivation
for reward in major depression. J Abnorm Psychol 2011.
47. Treadway MT, Bossaller NA, Shelton RC, Zald DH: Effort-based decision-making
in major depressive disorder: a translational model of motivational
anhedonia. J Abnorm Psychol 2012.
48. Berridge KC: The debate over dopamine’s role in reward: the case for
incentive salience. Psychopharmacology (Berl) 2007, 191:391–431.
49. Treadway MT, Zald DH: Reconsidering anhedonia in depression: lessons
from translational neuroscience. Neurosci Biobehav Rev 2011,
35:537–555.
50. Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, Votaw
JR, Goodman MM, Miller AH: Dopaminergic mechanisms of reduced basal
ganglia responses to hedonic reward during interferon alfa
administration. Arch Gen Psychiatry 2012, 69:1044–1053.
51. Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M,
Roiser JP, Neumeister A, Meyers N, Charney DS, Drevets WC: Neural
response to catecholamine depletion in unmedicated subjects with
major depressive disorder in remission and healthy subjects. Arch Gen
Psychiatry 2008, 65:521–531.
52. Hasler G, Luckenbaugh DA, Snow J, Meyers N, Waldeck T, Geraci M, Roiser J,
Knutson B, Charney DS, Drevets WC: Reward processing after
catecholamine depletion in unmedicated, remitted subjects with major
depressive disorder. Biol Psychiatry 2009, 66:201–205.
53. Heller AS, Johnstone T, Shackman AJ, Light SN, Peterson MJ, Kolden GG,
Kalin NH, Davidson RJ: Reduced capacity to sustain positive emotion in
major depression reflects diminished maintenance of fronto-striatal
brain activation. Proc Natl Acad Sci U S A 2009, 106:22445–22450.
54. Schildkraut JJ: The catecholamine hypothesis of affective disorders: a
review of supporting evidence. Am J Psychiatry 1965, 122:509–522.
55. Jacobs BL, Fornal CA: Activity of serotonergic neurons in behaving
animals. Neuropsychopharmacology 1999, 21:9S–15S.
56. Daubert EA, Condron BG: Serotonin: a regulator of neuronal morphology
and circuitry. Trends Neurosci 2010, 33:424–434.
57. Jasinska AJ, Lowry CA, Burmeister M: Serotonin transporter gene, stress
and raphe-raphe interactions: a molecular mechanism of depression.
Trends Neurosci 2012, 35:395–402.58. Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF: Medial
prefrontal cortex determines how stressor controllability affects behavior
and dorsal raphe nucleus. Nat Neurosci 2005, 8:365–371.
59. Amat J, Paul E, Watkins LR, Maier SF: Activation of the ventral medial
prefrontal cortex during an uncontrollable stressor reproduces both the
immediate and long-term protective effects of behavioral control.
Neuroscience 2008, 154:1178–1186.
60. Hammen C: Stress and depression. Annu Rev Clin Psychol 2005, 1:293–319.
61. Kessler RC: The effects of stressful life events on depression. Annu Rev
Psychol 1997, 48:191–214.
62. Kendler KS, Karkowski LM, Prescott CA: Causal relationship between
stressful life events and the onset of major depression. Am J Psychiatry
1999, 156:837–841.
63. Savitz JB, Drevets WC: Neuroreceptor imaging in depression. Neurobiol Dis
2013, 52:49–65.
64. Smith DF, Jakobsen S: Molecular neurobiology of depression: PET findings
on the elusive correlation with symptom severity. Front Psychiatry 2013, 4:8.
65. Willner P: Dopamine and depression: a review of recent evidence. I.
Empirical studies. Brain Res 1983, 287:211–224.
66. van Praag HM, Korf J, Schut D: Cerebral monoamines and depression. An
investigation with the probenecid technique. Arch Gen Psychiatry 1973,
28:827–831.
67. Salamone JD, Correa M: The mysterious motivational functions of
mesolimbic dopamine. Neuron 2012, 76:470–485.
68. Schultz W: Behavioral dopamine signals. Trends Neurosci 2007, 30:203–210.
69. Barch DM, Dowd EC: Goal representations and motivational drive in
schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull
2010, 36:919–934.
70. Treadway MT, Zald DH: Parsing anhedonia translational models of
reward-processing deficits in psychopathology. Curr Dir Psychol Sci 2013,
22:244–249.
71. Agren H, Reibring L: PET studies of presynaptic monoamine metabolism
in depressed patients and healthy volunteers. Pharmacopsychiatry 1994,
27:2–6.
72. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A,
Minifie C, Houle S, Hussey D, Kennedy SH: Lower dopamine transporter
binding potential in striatum during depression. Neuroreport 2001,
12:4121–4125.
73. Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT, Lu RB: Greater
availability of dopamine transporters in patients with major depression -
a dual-isotope SPECT study. Psychiatry Res 2008, 162:230–235.
74. Amsterdam JD, Newberg AB: A preliminary study of dopamine
transporter binding in bipolar and unipolar depressed patients and
healthy controls. Neuropsychobiology 2007, 55:167–170.
75. Laasonen-Balk T, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Lehtonen J,
Tiihonen J: Striatal dopamine transporter density in major depression.
Psychopharmacology (Berl) 1999, 144:282–285.
76. Rahmim A, Zaidi H: PET versus SPECT: strengths, limitations and
challenges. Nucl Med Commun 2008, 29:193–207.
77. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA: Dopaminergic
abnormalities in amygdaloid nuclei in major depression: a postmortem
study. Biol Psychiatry 2002, 52:740–748.
78. Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP: Clinical and psychometric
correlates of dopamine D2 binding in depression. Psychol Med 1997,
27:1247–1256.
79. D’Haenen HA, Bossuyt A: Dopamine D2 receptors in depression measured
with single photon emission computed tomography. Biol Psychiatry 1994,
35:128–132.
80. Gershon AA, Vishne T, Grunhaus L: Dopamine D2-like receptors and the
antidepressant response. Biol Psychiatry 2007, 61:145–153.
81. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M,
Cooper TB, Van Heertum R, Mann JJ, Laruelle M: Dopamine D(2) receptor
availability and amphetamine-induced dopamine release in unipolar
depression. Biol Psychiatry 2001, 50:313–322.
82. Hirvonen J, Karlsson H, Kajander J, Markkula J, Rasi-Hakala H, Nagren K,
Salminen JK, Hietala J: Striatal dopamine D2 receptors in medication-naive
patients with major depressive disorder as assessed with [11C]raclopride
PET. Psychopharmacology (Berl) 2008, 197:581–590.
83. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W: Dopamine
D2 receptor binding before and after treatment of major depression
measured by [123I]IBZM SPECT. Psychiatry Res 1999, 90:91–101.
Treadway and Pizzagalli Biology of Mood & Anxiety Disorders 2014, 4:5 Page 12 of 13
http://www.biolmoodanxietydisord.com/content/4/1/584. Cannon DM, Klaver JM, Peck SA, Rallis-Voak D, Erickson K, Drevets WC:
Dopamine type-1 receptor binding in major depressive disorder
assessed using positron emission tomography and [11C]NNC-112.
Neuropsychopharmacology 2009, 34:1277–1287.
85. Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML,
Focacci C, De Risio S: Dopamine transporter binding in depressed
patients with anhedonia. Psychiatry Res 2006, 147:243–248.
86. Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, Martinot J:
Decreased presynaptic dopamine function in the left caudate of
depressed patients with affective flattening and psychomotor
retardation. Am J Psychiatry 2001, 158:314–316.
87. Bragulat V, Paillere-Martinot ML, Artiges E, Frouin V, Poline JB, Martinot JL:
Dopaminergic function in depressed patients with affective flattening or
with impulsivity: [18 F]fluoro-L-dopa positron emission tomography
study with voxel-based analysis. Psychiatry Res 2007, 154:115–124.
88. Haroon E, Raison CL, Miller AH: Psychoneuroimmunology meets
neuropsychopharmacology: translational implications of the impact
of inflammation on behavior. Neuropsychopharmacology 2011,
37:137–162.
89. Takano H, Arakawa R, Nogami T, Suzuki M, Nagashima T, Fujiwara H, Kimura
Y, Kodaka F, Takahata K, Shimada H: Norepinephrine transporter
occupancy by nortriptyline in patients with depression: a positron
emission tomography study with (S, S)-[18F] FMeNER-D2. Int J
Neuropsychopharmaco 2013:1–8.
90. van Wingen GA, Tendolkar I, Urner M, van Marle H, Denys D, Verkes R-J,
Fernandez G: Short-term antidepressant administration reduces default
mode and task-positive network connectivity in healthy individuals
during rest. Neuroimage 2013.
91. Ossewaarde L, Verkes RJ, Hermans EJ, Kooijman SC, Urner M, Tendolkar I,
van Wingen GA, Fernandez G: Two-week administration of the combined
serotonin-noradrenaline reuptake inhibitor duloxetine augments
functioning of mesolimbic incentive processing circuits. Biol Psychiatry
2011, 70:568–574.
92. Bruhl AB, Jancke L, Herwig U: Differential modulation of emotion
processing brain regions by noradrenergic and serotonergic
antidepressants. Psychopharmacology (Berl) 2011, 216:389–399.
93. Bruhl AB, Kaffenberger T, Herwig U: Serotonergic and noradrenergic
modulation of emotion processing by single dose antidepressants.
Neuropsychopharmacology 2010, 35:521.
94. Ressler KJ, Nemeroff CB: Role of norepinephrine in the pathophysiology
and treatment of mood disorders. Biol Psychiatry 1999, 46:1219–1233.
95. Sanacora G, Treccani G, Popoli M: Towards a glutamate hypothesis of
depression: an emerging frontier of neuropsychopharmacology for
mood disorders. Neuropharmacology 2012, 62:63–77.
96. Altamura CA, Mauri MC, Ferrara A, Moro AR, D’Andrea G, Zamberlan F:
Plasma and platelet excitatory amino acids in psychiatric disorders. Am J
Psychiatry 1993, 150:1731–1733.
97. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH: Increased serum glutamate
in depressed patients. Arch Psychiatr Nervenkr 1982, 232:299–304.
98. Hashimoto K, Sawa A, Iyo M: Increased levels of glutamate in brains from
patients with mood disorders. Biol Psychiatry 2007, 62:1310–1316.
99. Yuksel C, Ongur D: Magnetic resonance spectroscopy studies of
glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010,
68:785–794.
100. Luykx JJ, Laban KG, van den Heuvel MP, Boks MP, Mandl RC, Kahn RS,
Bakker SC: Region and state specific glutamate downregulation in major
depressive disorder: a meta-analysis of (1)H-MRS findings. Neurosci
Biobehav Rev 2011, 36:198–205.
101. Jarnum H, Eskildsen SF, Steffensen EG, Lundbye-Christensen S, Simonsen CW,
Thomsen IS, Frund ET, Theberge J, Larsson EM: Longitudinal MRI study of
cortical thickness, perfusion, and metabolite levels in major depressive
disorder. Acta Psychiatr Scand 2011, 124:435–446.
102. Portella MJ, de Diego-Adelino J, Gomez-Anson B, Morgan-Ferrando R, Vives Y,
Puigdemont D, Perez-Egea R, Ruscalleda J, Enric A, Perez V: Ventromedial
prefrontal spectroscopic abnormalities over the course of depression:
a comparison among first episode, remitted recurrent and chronic patients.
J Psychiatr Res 2010, 45:427–434.
103. Merkl A, Schubert F, Quante A, Luborzewski A, Brakemeier EL, Grimm S,
Heuser I, Bajbouj M: Abnormal cingulate and prefrontal cortical
neurochemistry in major depression after electroconvulsive therapy.
Biol Psychiatry 2010, 69:772–779.104. Kondo DG, Hellem TL, Sung YH, Kim N, Jeong EK, Delmastro KK, Shi X,
Renshaw PF: Review: magnetic resonance spectroscopy studies of
pediatric major depressive disorder. Depress Res Treat 2011, 2011:650450.
105. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM,
Johayem A, Burger C, Auberson YP, Sovago J, Stockmeier CA, Buck A, Hasler
G: Reduced metabotropic glutamate receptor 5 density in major
depression determined by [11C]ABP688 PET and postmortem study.
Am J Psychiatry 2011, 168:727–734.
106. Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, Scheidegger M,
Berthold T, Gomez-Mancilla B, Seifritz E: Increased metabotropic glutamate
receptor subtype 5 availability in human brain after one night without sleep.
Biol Psychiatry 2013.
107. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS,
Krystal JH: Antidepressant effects of ketamine in depressed patients.
Biol Psychiatry 2000, 47:351–354.
108. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA,
Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate
antagonist in treatment-resistant major depression. Arch Gen Psychiatry
2006, 63:856–864.
109. Luscher B, Shen Q, Sahir N: The GABAergic deficit hypothesis of major
depressive disorder. Mol Psychiatry 2010, 16:383–406.
110. Petty F, Schlesser MA: Plasma GABA in affective illness. A preliminary
investigation. J Affect Disord 1981, 3:339–343.
111. Petty F, Sherman AD: GABAergic modulation of learned helplessness.
Pharmacol Biochem Behav 1981, 15:567–570.
112. Gerner RH, Hare TA: CSF GABA in normal subjects and patients with
depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry
1981, 138:1098–1101.
113. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC:
Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid
levels in major depression determined using proton magnetic resonance
spectroscopy. Arch Gen Psychiatry 2007, 64:193–200.
114. Gabbay V, Mao X, Klein RG, Ely BA, Babb JS, Panzer AM, Alonso CM, Shungu
DC: Anterior cingulate cortex gamma-aminobutyric acid in depressed
adolescents: relationship to anhedonia. Arch Gen Psychiatry 2012,
69:139–149.
115. Radley JJ, Sawchenko PE: A common substrate for prefrontal and
hippocampal inhibition of the neuroendocrine stress response. J Neurosci
2011, 31:9683–9695.
116. Radley JJ, Gosselink KL, Sawchenko PE: A discrete GABAergic relay
mediates medial prefrontal cortical inhibition of the neuroendocrine
stress response. J Neurosci 2009, 29:7330–7340.
117. Homan P, Drevets WC, Hasler G: Neural correlates of free T3 alteration
after catecholamine depletion in subjects with remitted major
depressive disorder and in controls. Psychopharmacology (Berl) 2014,
231:409–417.
118. Homan P, Grob S, Milos G, Schnyder U, Hasler G: Reduction in total plasma
ghrelin levels following catecholamine depletion: relation to bulimic and
depressive symptoms. Psychoneuroendocrinology 2013.
119. McEwen BS: Physiology and neurobiology of stress and adaptation:
central role of the brain. Physiol Rev 2007, 87:873–904.
120. Sapolsky RM: Glucocorticoids and hippocampal atrophy in
neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925–935.
121. Radley JJ, Rocher AB, Miller M, Janssen WG, Liston C, Hof PR, McEwen BS,
Morrison JH: Repeated stress induces dendritic spine loss in the rat
medial prefrontal cortex. Cereb Cortex 2006, 16:313–320.
122. Cook SC, Wellman CL: Chronic stress alters dendritic morphology in rat
medial prefrontal cortex. J Neurobiol 2004, 60:236–248.
123. Cerqueira JJ, Pego JM, Taipa R, Bessa JM, Almeida OF, Sousa N:
Morphological correlates of corticosteroid-induced changes in prefrontal
cortex-dependent behaviors. J Neurosci 2005, 25:7792–7800.
124. McEwen BS: Stress and hippocampal plasticity. Annu Rev Neurosci 1999,
22:105–122.
125. Treadway MT, Grant MM, Ding Z, Hollon SD, Gore JC, Shelton RC: Early
adverse events, HPA activity and rostral anterior cingulate volume in
MDD. PLoS One 2009, 4:e4887.
126. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL:
A meta-analysis of cytokines in major depression. Biol Psychiatry 2010,
67:446–457.
127. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R,
Seligman DA, Schmidt K: The relationship of depression and stressors to
Treadway and Pizzagalli Biology of Mood & Anxiety Disorders 2014, 4:5 Page 13 of 13
http://www.biolmoodanxietydisord.com/content/4/1/5immunological assays: a meta-analytic review. Brain Behav Immun 2001,
15:199–226.
128. Shelton RC, Miller AH: Eating ourselves to death (and despair): the
contribution of adiposity and inflammation to depression. Prog Neurobiol
2010, 91:275–299.
129. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B,
Thurmond L, Bilello JA: Assessment of a multi-assay, serum-based
biological diagnostic test for major depressive disorder: a Pilot and
Replication Study. Mol Psychiatry 2011.
130. Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role
of cytokines in the pathophysiology of major depression. Biol Psychiatry
2009, 65:732–741.
131. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From
inflammation to sickness and depression: when the immune system
subjugates the brain. Nat Rev Neurosci 2008, 9:46–56.
132. Dantzer R, Meagher MW, Cleeland CS: Translational approaches to
treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol 2012,
9:414–426.
133. Felger JC, Mun J, Kimmel HL, Nye JA, Drake DF, Hernandez CR, Freeman AA,
Rye DB, Goodman MM, Howell LL: Chronic interferon-α decreases
dopamine 2 receptor binding and striatal dopamine release in
association with anhedonia-like behavior in nonhuman primates.
Neuropsychopharmacology 2013.
134. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, Kalin NH,
Ratti E, Nemeroff CB, Miller AH: Effects of interferon-alpha on rhesus
monkeys: a nonhuman primate model of cytokine-induced depression.
Biol Psychiatry 2007, 62:1324–1333.
135. Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA, Baqi Y, Mueller
CE, Correa M, Salamone JD: Effort-related motivational effects of the
pro-inflammatory cytokine interleukin 1-beta: studies with the
concurrent fixed ratio 5/chow feeding choice task. Psychopharmacology
(Berl) 2014, 231:727–736.
136. Hannestad J, DellaGioia N, Gallezot J-D, Lim K, Nabulsi N, Esterlis I, Pittman
B, Lee J-YO, Pelletier D, ÄôConnor KC: The neuroinflammation marker
translocator protein is not elevated in individuals with mild-to-moderate
depression: A [< sup > 11</sup > C] PBR28 PET study. Brain Behav Immun
2013, 33:131–138.
137. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR:
Inflammation-induced anhedonia: endotoxin reduces ventral striatum
responses to reward. Biol Psychiatry 2010, 68:748–754.
138. McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco
AR, Craddock RC, Mayberg HS: Toward a neuroimaging treatment
selection biomarker for major depressive disorder. JAMA Psychiatry 2013,
70:821–829.
139. Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar
EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH,
Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD:
Deep brain stimulation of the ventral capsule/ventral striatum for
treatment-resistant depression. Biol Psychiatry 2009, 65:267–275.
140. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C,
Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant
depression. Neuron 2005, 45:651–660.
141. Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA,
Dunner DL, Lanocha K, Solvason HB, Demitrack MA: Transcranial magnetic
stimulation (TMS) for major depression: a multisite, naturalistic,
observational study of acute treatment outcomes in clinical practice.
Depress Anxiety 2012, 29:587–596.
142. Raison CL, Miller AH: Is depression an inflammatory disorder? Curr
Psychiatry Rep 2011, 13:467–475.
143. Cooper JC, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology.
8th edition. New York: Oxford University Press; 2003.
144. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C,
Wang P: Research domain criteria (RDoC): toward a new classification
framework for research on mental disorders. Am J Psychiatry 2010,
167:748–751.
145. Akil H, Brenner S, Kandel E, Kendler KS, King MC, Scolnick E, Watson JD,
Zoghbi HY: Medicine. The future of psychiatric research: genomes and
neural circuits. Science 2010, 327:1580–1581.
146. Nestler EJ, Hyman SE: Animal models of neuropsychiatric disorders.
Nat Neurosci 2010, 13:1161–1169.147. Deisseroth K: Circuit dynamics of adaptive and maladaptive behaviour.
Nature 2014, 505:309–317.
148. Bullmore ET, Bassett DS: Brain graphs: graphical models of the human
brain connectome. Annu Rev Clin Psychol 2011, 7:113–14.
149. Bullmore E, Sporns O: Complex brain networks: graph theoretical analysis
of structural and functional systems. Nat Rev Neurosci 2009, 10:186–198.
150. Buckholtz JW, Meyer-Lindenberg A: Psychopathology and the human
connectome: toward a transdiagnostic model of risk for mental illness.
Neuron 2012, 74:990–1004.
151. Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, Penny WD: Statistical
Parametric Mapping: the Analysis of Functional Brain Images. Academic; 2011.
152. Walter M, Henning A, Grimm S, Schulte RF, Beck J, Dydak U, Schnepf B,
Boeker H, Boesiger P, Northoff G: The relationship between aberrant
neuronal activation in the pregenual anterior cingulate, altered
glutamatergic metabolism, and anhedonia in major depression. Arch Gen
Psychiatry 2009, 66:478–486.
153. Kring AM, Sloan DM: Emotion Regulation and Psychopathology: a
Transdiagnostic Approach to Etiology and Treatment. New York, NY: The
Guilford Press; 2010.
154. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE: Probing brain
reward system function in major depressive disorder: altered response
to dextroamphetamine. Arch Gen Psychiatry 2002, 59:409–416.
155. Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S,
Busto UE: Functional neuroanatomical substrates of altered reward
processing in major depressive disorder revealed by a dopaminergic
probe. Arch Gen Psychiatry 2005, 62:1228–1236.
156. Kahneman D, Riis J: Living, and thinking about it: two perspectives on
life. In The science of well-being. Edited by Huppert FA, Baylis N, Keverne B.
New York, NY: Oxford University Press; 2005.
157. Conner TS, Barrett LF: Trends in ambulatory self-report: the role of
momentary experience in psychosomatic medicine. Psychosom Med 2012,
74:327–337.
158. Kahneman D, Krueger AB, Schkade D, Schwarz N, Stone AA: Would you be
happier if you were richer? A focusing illusion. Science 2006,
312:1908–1910.
159. Kahneman D, Deaton A: High income improves evaluation of life but not
emotional well-being. Proc Natl Acad Sci 2010, 107:16489–16493.
160. Schwarz N: Retrospective and concurrent self-reports: the rationale for
real-time data capture. In The Science of Real-Time Data Caputre:
Self-Reports in Health Research. Google e-book; 2007:11–26.
161. Strauss GP, Gold JM: A new perspective on anhedonia in schizophrenia.
Am J Psychiatry 2012.
162. Kagan J: A trio of concerns. Perspect Psychol Sci 2007, 2:361–376.
163. Beck AT, Haigh E: The generic cognitive model. Annu Rev Clin Psychol 2013, 10.
doi:10.1186/2045-5380-4-5
Cite this article as: Treadway and Pizzagalli: Imaging the
pathophysiology of major depressive disorder - from localist models to
circuit-based analysis. Biology of Mood & Anxiety Disorders 2014 4:5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
